Madrigal Pharmaceuticals
CompanyUnited States
Madrigal Pharmaceuticals develops one asset, approved (resmetirom in fibrosis). Mostly small molecule acting on Mitochondrial biogenesis (PGC-1α), lipid and ceramide metabolism and THRB; based in the United States.
- Assets
- 1
- Furthest
- Approved
- Trials
- 13
- Signals
- 3
Pipeline
1Selective thyroid hormone receptor beta agonist that reduces hepatic fat accumulation
ApprovedSmall moleculeMitochondrial biogenesis (PGC-1α)Lipid and ceramide metabolismfibrosisliver cirrhosis
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms4
- Trials13
- Signals5
- Similar companies6
Updated 7 Oct 2026 · 28 sources